Skip to main content
Erschienen in:

08.08.2022 | Mini-review

Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature

verfasst von: Masato Aoki, Hisamitsu Takaya, Tomoyuki Otani, Hidekatsu Nakai, Kosuke Murakami, Noriomi Matsumura

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Ovarian teratoid carcinosarcoma involves an epithelial tumor of the Müllerian duct and an immature neuroepithelium, which is a characteristic of immature teratomas. Here, we describe the case of a 60-year-old woman who underwent surgery for a stage IC3 ovarian malignancy. The tumor showed a variety of histological features, including clear cell carcinoma, immature teratoma, and rhabdomyosarcoma, and a PIK3CA mutation was detected at the same locus in each. Two months after surgery and before the start of chemotherapy, multiple bone and liver metastases were found. Four courses of combination therapy with vincristine, actinomycin D and cyclophosphamide, the standard chemotherapy regimen for pediatric rhabdomyosarcoma, were administered, and a complete response was achieved. After a 2-month rest period, the patient developed recurrent peritoneal dissemination and underwent 6 courses of paclitaxel, carboplatin, and bevacizumab chemotherapy, resulting in a partial response. This is the eighth reported case of ovarian teratoid carcinosarcoma. This tumor has a very aggressive course, but initially responds to chemotherapy. However, survival over 5 years has not been reported, and elucidation of the pathogenesis and development of new treatment methods are needed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Ehrmann RL, Weidner N, Welch WR et al (1990) Malignant mixed Mullerian tumor of the ovary with prominent neuroectodermal differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol 9:272–282CrossRef Ehrmann RL, Weidner N, Welch WR et al (1990) Malignant mixed Mullerian tumor of the ovary with prominent neuroectodermal differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol 9:272–282CrossRef
2.
Zurück zum Zitat Tanimoto A, Arima N, Hayashi R et al (2001) Teratoid carcinosarcoma of the ovary with prominent neuroectodermal differentiation. Pathol Int 51:829–832CrossRef Tanimoto A, Arima N, Hayashi R et al (2001) Teratoid carcinosarcoma of the ovary with prominent neuroectodermal differentiation. Pathol Int 51:829–832CrossRef
3.
Zurück zum Zitat Ohishi Y, Kaku T, Kaneki E et al (2007) Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study. Gynecol Oncol 105:548–552CrossRef Ohishi Y, Kaku T, Kaneki E et al (2007) Malignant ovarian tumor composed of endometrioid adenocarcinoma, clear cell adenocarcinoma, squamous cell carcinoma, yolk sac tumor and immature teratoma with prominent neuroectodermal and rhabdomyosarcomatous differentiation: a case study. Gynecol Oncol 105:548–552CrossRef
4.
Zurück zum Zitat Garcia-Galvis OF, Cabrera-Ozoria C, Fernandez JA et al (2008) Malignant Mullerian mixed tumor of the ovary associated with york sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol 27:515–520CrossRef Garcia-Galvis OF, Cabrera-Ozoria C, Fernandez JA et al (2008) Malignant Mullerian mixed tumor of the ovary associated with york sac tumor, neuroepithelial and trophoblastic differentiation (teratoid carcinosarcoma). Int J Gynecol Pathol 27:515–520CrossRef
5.
Zurück zum Zitat Matsuura Y, Kitajima M, Hachisuga T et al (2010) Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res 36:907–911CrossRef Matsuura Y, Kitajima M, Hachisuga T et al (2010) Malignant mixed müllerian tumor with malignant neuroectodermal components (teratoid carcinosarcoma) of the ovary: Report of a case with clinicopathologic findings. J Obstet Gynaecol Res 36:907–911CrossRef
6.
Zurück zum Zitat Nasser H, Morris RT, Fathallah L (2011) Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: Case report with review of the literature. Pathol Res Pract 207:202–206CrossRef Nasser H, Morris RT, Fathallah L (2011) Ovarian malignant mixed mullerian tumor with primitive neuroectodermal differentiation: Case report with review of the literature. Pathol Res Pract 207:202–206CrossRef
7.
Zurück zum Zitat Fox C, Allen N, Schimp V et al (2019) Ovarian teratoid carcinosarcoma is an aggressive tumor of probable Mullerian derivation with a carcinosarcomatous and mixed germ-cell morphology. Case Rep Oncol 12:241–247CrossRef Fox C, Allen N, Schimp V et al (2019) Ovarian teratoid carcinosarcoma is an aggressive tumor of probable Mullerian derivation with a carcinosarcomatous and mixed germ-cell morphology. Case Rep Oncol 12:241–247CrossRef
8.
Zurück zum Zitat Dunlap J, Le C, Shukla A et al (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120:409–418CrossRef Dunlap J, Le C, Shukla A et al (2010) Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat 120:409–418CrossRef
9.
Zurück zum Zitat Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:57–61 Pao W, Wang TY, Riely GJ et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:57–61
10.
Zurück zum Zitat George E, Manivel JC, Dehner LP et al (1991) Malignant mixed Müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 22:215–223CrossRef George E, Manivel JC, Dehner LP et al (1991) Malignant mixed Müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 22:215–223CrossRef
11.
Zurück zum Zitat Roth LM, Talerman A, Levy T et al (2011) Yolk sac tumors in older women arising from epithelial ovarian tumors or with no detectable epithelial component. Int J Gynecol Pathol 30:442–451CrossRef Roth LM, Talerman A, Levy T et al (2011) Yolk sac tumors in older women arising from epithelial ovarian tumors or with no detectable epithelial component. Int J Gynecol Pathol 30:442–451CrossRef
12.
Zurück zum Zitat Murakami R, Matsumura N, Brown JB et al (2017) Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation Gene Networks. Am J Pathol 187:2246–2258CrossRef Murakami R, Matsumura N, Brown JB et al (2017) Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation Gene Networks. Am J Pathol 187:2246–2258CrossRef
13.
Zurück zum Zitat Skala SL, Liu CJ, Udager AM et al (2020) Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation. Mod Pathol 33:1989–2000CrossRef Skala SL, Liu CJ, Udager AM et al (2020) Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation. Mod Pathol 33:1989–2000CrossRef
14.
Zurück zum Zitat Abou-Taleb H, Yamaguchi K, Matsumura N et al (2016) Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. Oncotarget 7:54758–54770CrossRef Abou-Taleb H, Yamaguchi K, Matsumura N et al (2016) Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. Oncotarget 7:54758–54770CrossRef
15.
Zurück zum Zitat Ruymann FB (2003) The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr Oncol Rep 5:505–509CrossRef Ruymann FB (2003) The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr Oncol Rep 5:505–509CrossRef
Metadaten
Titel
Ovarian teratoid carcinosarcoma with a PIK3CA mutation: a case report and review of the literature
verfasst von
Masato Aoki
Hisamitsu Takaya
Tomoyuki Otani
Hidekatsu Nakai
Kosuke Murakami
Noriomi Matsumura
Publikationsdatum
08.08.2022
Verlag
Springer Nature Singapore
Erschienen in
International Cancer Conference Journal / Ausgabe 4/2022
Elektronische ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-022-00571-w

Neu im Fachgebiet Onkologie

Positive Phase IIb-Studie zu mRNA-gestützter CAR-T bei Myasthenia gravis

Eine auf das B-Zell-Reifungsantigen gerichtete mRNA-basierte CAR-T-Zell-Therapie wurde jetzt in einer ersten Phase IIb-Studie zur Behandlung der generalisierten Myasthenia gravis mit Placebo verglichen.

NSCLC: Hirnmetastasen durch elektrische Felder eindämmen

Zur Behandlung von Hirnmetasen bei nicht-kleinzelligem Lungenkrebs (NSCLC) stehen verschiedene Optionen zur Verfügung. TTFields – eine lokoregionäre, nicht-invasive physikalische Therapie – könnte sich hier einreihen.

Kontrollkoloskopie nach Polypektomie: Wann ist eine zweite Untersuchung nötig?

Wann benötigen polypektomierte Patienten und Patientinnen mehr als eine endoskopische Nachsorgeuntersuchung? Eine Kohortenstudie aus Großbritannien legt eine konkrete Strategie nahe.

Wenn die Krebstherapie die Identität verändert

Tumortherapien können die Fingerbeere so verändern, dass eine Fingerabdruck-abhängige Identitätskontrolle fehlschlägt. Dafür sprechen zumindest Daten aus der Literatur, die Forschende nun erstmals für ein Review zusammengetragen haben. Vieles ist im Moment aber noch unklar.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.